ArticleJournal of substance abuse treatment2017
The relationship between diversion-related attitudes and sharing and selling buprenorphine.
Article in Journal of substance abuse treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial.JAMA internal medicine · 2026Trial
- Medication Sharing Among Older Adults in South Korea: A Qualitative Study.Patient preference and adherence · 2026Article
- Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010‒2017).Journal of the American College of Emergency Physicians open · 2024Article
- Article
- Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.Harm reduction journal · 2023Article
- An uncontrolled pilot trial of a buprenorphine dispensing device to enhance outpatient treatment for opioid use disorder.Heroin addiction and related clinical problems · 2023Article
- Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.Substance use & misuse · 2023Article
- Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use.Drug and alcohol dependence reports · 2022Article
- Toward evaluation of disseminated effects of medications for opioid use disorder within provider-based clusters using routinely-collected health data.Statistics in medicine · 2022Article
- "We'll be able to take care of ourselves" - A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs.Substance abuse · 2021Article
- Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?The International journal on drug policy · 2020Article
- Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.Addiction science & clinical practice · 2019Article
- Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?Substance abuse · 2019Article
- Perceptions and practices addressing diversion among US buprenorphine prescribers.Drug and alcohol dependence · 2018Article
- Increasing diversion of methadone in Vancouver, Canada, 2005-2015.Journal of substance abuse treatment · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveBuprenorphine medication-assisted treatment (B-MAT) is an efficacious and popular outpatient treatment for opioid use disorder. However, the likelihood of buprenorphine diversion is a public health concern. We examined the relationship between attitudes toward diversion as predictors of both sharing and selling buprenorphine.
methodParticipants (n=476) were patients undergoing short-term inpatient opioid detoxification. Multinomial logistic regression was used to estimate the adjusted association of sharing and selling buprenorphine with demographics, substance use behaviors, and attitudes toward sharing and selling buprenorphine.
resultsAmong the two hundred persons who had ever been prescribed buprenorphine (73.4% male, 89% heroin users), 50.5% reported they had shared buprenorphine and 28.0% reported they had sold buprenorphine. Controlling for other covariates, the odds of sharing buprenorphine were 3.17 (95% CI 1.21; 8.32) times higher for persons who agreed that it was "right to share buprenorphine with dope sick friends" than for those who did not agree with this attitude. Attitudes toward selling (OR 2.92; 95% CI 1.35; 6.21) and sharing (OR 4.12; 95% CI 1.64; 10.32) buprenorphine were the only significant correlates of selling, with the odds of selling exponentially greater among persons with favorable attitudes toward sharing or selling buprenorphine.
conclusionsAlthough considered diversion, sharing B-MAT is normative among B-MAT patients. Assessing B-MAT patients' attitudes about diversion may help identify patients requiring enhanced oversight, education, or intervention aimed at modifying attitudes to reduce their likelihood to share or sell buprenorphine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.